X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of relapsed/refractory large b-cell lymphoma.
Lead Product(s): Axicabtagene Ciloleucel
Therapeutic Area: Oncology Product Name: Yescarta
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
Under the expanded collaboration, Kite has exercised its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma, which is comprised of ARC-T cells and SparX proteins that target BCMA.
Lead Product(s): ACLX-001
Therapeutic Area: Oncology Product Name: ACLX-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Arcellx
Deal Size: $285.0 million Upfront Cash: $85.0 million
Deal Type: Expanded Collaboration November 15, 2023
Details:
Under the agreement, Kite will gain access to Epic Bio’s gene regulation platform to potentially develop next-generation cancer cell therapies and Epic Bio will develop constructs for Kite-selected targets for use in CAR T-cell therapies directed to blood cancers.
Lead Product(s): CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Epic Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 31, 2023
Details:
Under the agreement, Kite obtains marketing authorization in Japan for Yescarta® (axicabtagene ciloleucel), a CAR T-cell therapy, and is approved in Japan for the treatment of patients with relapsed or refractory large B-cell lymphomas, a type of non-Hodgkin lymphoma.
Lead Product(s): Axicabtagene Ciloleucel
Therapeutic Area: Oncology Product Name: Yescarta
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: $250.0 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement June 22, 2023
Details:
The fundings will advance the development of Ensoma’s Engenious™ in vivo engineered cell therapy platform and pipeline of genomic medicines for immuno-oncology, genetic disease and other therapeutic applications.
Lead Product(s): Genomic Medicine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Ensoma
Deal Size: $135.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 16, 2023
Details:
Yescarta ® (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells. It is indicated for treating relapsed/refractory large B-cell lymphoma.
Lead Product(s): Axicabtagene Ciloleucel
Therapeutic Area: Oncology Product Name: Yescarta
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Tmunity Therapeutics is developing TmXX-01 for the development of B cell malignancies. The acquisition will provide Kite with pre-clinical and clinical programs, including an armored CAR T technology platform.
Lead Product(s): TmXX-01
Therapeutic Area: Oncology Product Name: TmXX-01
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 22, 2023
Details:
KTE-X19 (brexucabtagene autoleucel) is a modified autologous chimeric antigen receptor T cell therapy employing a modified murine anti-CD19 single-chain variable linked to CD28 and CD3ζ co-stimulatory domains for relapsed and refractory B-Cell acute lymphoblastic leukemia.
Lead Product(s): Brexucabtagene Autoleucel
Therapeutic Area: Oncology Product Name: Tecartus
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
Kite and Arcellx were jointly working to advance and commercialize the CART-ddBCMA asset for relapsed or refractory multiple myeloma in U.S., and Kite was supposed to commercialize outside the U.S.
Lead Product(s): CART-ddBCMA
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Arcellx
Deal Size: $325.0 million Upfront Cash: $225.0 million
Deal Type: Termination January 30, 2023
Details:
Yescarta (axicabtagene ciloleucel) is a CAR T-cell therapy directed against CD19 (a cell membrane protein), which harnesses a patient’s own immune system to fight cancer.
Lead Product(s): Axicabtagene Ciloleucel
Therapeutic Area: Oncology Product Name: Yescarta
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
